# Fasedienol (Organization)
---
Who / What
Fasedienol is a **chemical compound** known as 4-androstadienol or 4,16-androstadien-3β-ol, developed as a pheromine under investigation for its potential therapeutic uses. It is being explored by VistaGen Therapeutics in nasal spray formulations for the acute treatment of social anxiety disorder (as needed) and is also studied for generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).
---
Background & History
Fasedienol is a positional isomer of the endogenous pheromone **androstadienol** (5-androstadienol). Originally identified through research into pheromonal influences on social behavior, it was initially developed under code names PH94B and Aloradine. The compound entered clinical investigation as part of VistaGen Therapeutics’ efforts to explore its role in modulating anxiety-related conditions.
---
Why Notable
Fasedienol holds significance due to its potential therapeutic applications in treating anxiety disorders, including social anxiety disorder (SAD), GAD, and PTSD. As a pheromine, it may offer a novel mechanism of action by influencing physiological responses tied to stress and emotional regulation. Its development as a nasal spray formulation suggests a targeted delivery method that could improve patient compliance and efficacy.
---
In the News
While not widely publicized in recent years, Fasedienol remains under active investigation by VistaGen Therapeutics for its potential in anxiety disorders. The compound’s positioning as a pheromine-based treatment aligns with emerging research into non-pharmacological or minimally invasive interventions for mental health conditions, making it relevant in the evolving landscape of psychiatric therapeutics.
---
Key Facts
---
